Welcome!

Government Cloud Authors: Elizabeth White, Pat Romanski, Dana Gardner, Liz McMillan, Gopala Krishna Behara

News Feed Item

NeuroVive and the European Brain Injury Consortium Sign TBI Clinical Trial Collaboration

Phase II/III Study Will Determine the Safety and Efficacy of NeuroSTAT(R) in Patients with Moderate to Severe Traumatic Brain Injury

WASHINGTON, DC and LUND, SWEDEN -- (Marketwire) -- 03/03/11 -- In advance of The Traumatic Brain Injury Conference in Washington, DC on March 7, NeuroVive is pleased to announce that it has signed an agreement with the European Brain Injury Consortium (EBIC) to conduct a European multi-center Phase II/III clinical trial of NeuroSTAT® for neuroprotection in patients with traumatic brain injury (TBI). The goal of the collaboration is to secure the highest possible study quality and compliance with clinical standards to support NeuroSTAT®'s rapid progress toward commercialization. To this end, NeuroVive will work closely with EBIC's key European experts in the field of neurotrauma and acute brain injuries.

NeuroVive will manage the study in close collaboration with the EBIC group and a clinical research organization (CRO) to be selected. The collaboration with EBIC includes development of the study protocol, site selection, patient recruitment, and statistical support. This adaptive design Phase II/III study will determine the safety and efficacy of NeuroSTAT® in moderate to severe TBI.

TBI is a leading cause of death and disability among a predominantly young male population, mostly victims of motor vehicle accidents. TBI is composed of two stages: a first stage of initial brain damage; and a second stage of mitochondrial collapse inside brain cells leading to additional cell death, brain damage and disability. The active agent in the NeuroSTAT® formula is a proven mitochondrial protector that in animal studies is a potent neuroprotectant against TBI. There are over 10 million TBI cases per year worldwide. Annually in the U.S., head trauma sends two million people to the emergency room and a half a million have injuries severe enough to be admitted to the hospital. TBI kills 50,000 people and leaves 80,000 people disabled. The annual market for an effective TBI drug is estimated to exceed US$1 billion in the U.S. and Europe.

NeuroVive CEO Mikael Bronnegard comments:

"We are very pleased to collaborate on the NeuroSTAT® Phase II/III clinical trial with a highly respected organization like EBIC, comprising key opinion leaders and medical experts in the field of neurotrauma in Europe. Through this collaboration, we have an excellent opportunity to advance the development of NeuroSTAT® toward clinical use in treating millions of TBI patients worldwide."

Professor Andrew Maas, Chairman of EBIC, Professor and Chairman Department of Neurosurgery at University Hospital Antwerp, Belgium comments:

"This clinical trial is of great interest to us. The need for international collaboration in the conduct of research in the clinical management of head injury has never been greater, but rigorous evaluation must be carried out on a range of approaches that include new pharmacological agents. Therefore, the collaboration with NeuroVive in conducting a clinical trial in TBI patients with their product NeuroSTAT® offers a unique way to address all critical issues in study design, selection of end-points, patient recruitment, study monitoring and, finally, study analysis."

About NeuroSTAT®

NeuroVive conducts research and development of cyclosporin-based drugs, known as cyclophilin D inhibitors, to protect mitochondria in nerve cells. Mitochondrial collapse in nerve cells after the initial brain injury leads to additional cell death and brain damage. Protecting the mitochondria in nerve cells is a key emerging strategy in treating TBI by reducing overall damage and eventual disability. Cyclosporin-A, the active ingredient in NeuroVive's first product NeuroSTAT®, has for years been used for immunosuppression in organ transplantation.

In contrast to currently commercially available intravenous cyclosporin-A used for immune suppression, NeuroSTAT® does not contain cremophor® or ethanol. Importantly, studies have reported that cremophor® can cause hypersensitivity reactions (anaphylaxis) in treated patients. With NeuroSTAT®, a cremophor®- and ethanol-free product, NeuroVive's objective is to provide healthcare providers worldwide with a non-allergenic advanced new formulation of cyclosporin-A for neuroprotection in the treatment of moderate to severe neurological damage in patients with traumatic brain injury.

NeuroSTAT® is a designated orphan drug for moderate and severe TBI in Europe and the U.S.

About the European Brain Injury Consortium

Constituted in 1995, the European Brain Injury Consortium (EBIC) is a network of European neurological research and medical units highly experienced in the care of patients with brain injuries. EBIC was founded to promote international, multi-center, interdisciplinary research aimed at improving the outcomes of patients who have suffered head injury or other acute brain damage.

About NeuroVive

NeuroVive Pharmaceutical AB is a Swedish drug development company whose primary mission is to develop drugs that protect nerve cells. In addition to conducting clinical trials of NeuroSTAT® - the first cyclophilin-D-inhibiting mitochondrial protectant - NeuroVive is researching and developing variants of cyclophilin-D-inhibiting cyclosporins and new ways of transporting these drugs across the blood-brain barrier to the central nervous system. NeuroVive's shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Contacts:
NeuroVive Pharmaceutical AB
Mikael Bronnegard, MD
CEO
011 46 46 288 0110 or Cell: 011 46 70 299 6264
[email protected]
www.neurovive.com

& Company Strategies Inc. - Media Contact
Steve Campbell, APR
Campbell, Communications and Public Relations
604 888-5267 or Cell: 604 803-8267
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
Bill Schmarzo, Tech Chair of "Big Data | Analytics" of upcoming CloudEXPO | DXWorldEXPO New York (November 12-13, 2018, New York City) today announced the outline and schedule of the track. "The track has been designed in experience/degree order," said Schmarzo. "So, that folks who attend the entire track can leave the conference with some of the skills necessary to get their work done when they get back to their offices. It actually ties back to some work that I'm doing at the University of San...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Dynatrace is an application performance management software company with products for the information technology departments and digital business owners of medium and large businesses. Building the Future of Monitoring with Artificial Intelligence. Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more busine...
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
Chris Matthieu is the President & CEO of Computes, inc. He brings 30 years of experience in development and launches of disruptive technologies to create new market opportunities as well as enhance enterprise product portfolios with emerging technologies. His most recent venture was Octoblu, a cross-protocol Internet of Things (IoT) mesh network platform, acquired by Citrix. Prior to co-founding Octoblu, Chris was founder of Nodester, an open-source Node.JS PaaS which was acquired by AppFog and ...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...